美股详情

本页面由Tiger Fintech (Singapore) Pte. Ltd.提供服务

减肥药

1,229.17

-22.0642-1.76%

涨家数：3

跌家数：4

平家数：- -

市盈率：- -

高：1,257.62

开：1,252.13

低：1,216.60

收：1,251.24

数据加载中...

辉瑞被减肥药“搞怕了”

Ofweek维科网

辉瑞4月15日成交额为11.68亿美元

诺和诺德4月15日成交额为3.85亿美元

礼来4月15日成交额为18.62亿美元

安进4月15日成交额为7.64亿美元

联邦制药(3933.HK)：UBT251授权给诺和诺德创新转型初见成效

辉瑞因潜在肝脏损伤停止减肥药测试Pfizer Ends Testing of Obesity Pill After Possible Liver Injury

诺和诺德盘中异动大幅下挫3.01%

【LVMH集团跌超7%，在欧股“十一罗汉”中表现最差，并领跌一众奢侈品概念股】周二，阿斯麦控股荷兰阿姆斯特丹股价收涨2.61%，报605.40欧元。诺和诺德哥本哈根股价收跌2.34%，报425.70。LVMH集团收跌7.82%，欧莱雅跌2%，阿斯利康和赛诺菲至多跌0.39%，雀巢则收涨0.38%，罗氏、诺华、德国思爱普Sap、葛兰素史克至多涨1.78%。欧洲奢侈品概念股中，除了路易威登母公司LVMH集团之外，开云集团跌5.22%，博柏利跌4.55%，人头马君度、保乐力加、雨果博斯、斯沃琪集团、瑞士历峰集团跌3.69%-0.88%，爱马仕则收涨0.21%。

Viking Therapeutics, Inc.盘中异动股价大跌5.01%报23.34美元

礼来：携手本土生态伙伴加速赋能医药创新

BUZZ-实验性减肥药物在小鼠体内显示出前景后，斯凯生物科学公司业绩上升

1名受试者出现肝损伤，辉瑞终止一款口服减肥药临床开发，死磕小分子GLP-1

辉瑞(PFE.US)研发受挫引发收购猜测减肥药新贵股价大涨

辉瑞又双叒叕放弃一款口服 GLP-1，肥胖管线仅剩 1 款药物

Insight数据库

辉瑞4月14日成交额为13.66亿美元

诺和诺德4月14日成交额为5.33亿美元

辉瑞的GLP失败了

生物药大时代

安进4月14日成交额为7.28亿美元

金十数据整理：每日美股市场要闻速递（4月14日，周一）

{"basename":"/hans","ssrTDKData":{"titleTemplate":"%s - 老虎证券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎证券,老虎证券开户,老虎券商,老虎证券官网,老虎证券app,tigertrade老虎证券,股票,炒股,新加坡股票交易平台,投资,投资理财","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hans/stock/BK4599/news?page=3"},"companyName":"老虎证券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"BK4599","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"BK4599\",,,,,undefined,":{"symbol":"BK4599","market":"US","secType":"PLATE","nameCN":"减肥药","latestPrice":1229.1708,"timestamp":1745265599999,"preClose":1251.235,"halted":0,"volume":57826241,"delay":0,"changeRate":-0.017634,"floatShares":0,"shares":0,"eps":0,"marketStatus":"未开盘","change":-22.064209,"latestTime":"04-21 16:00:00 EDT","open":1252.1276,"high":1257.6151,"low":1216.6044,"amount":4848730365.862926,"amplitude":0.032776,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"tradingStatus":0,"nextMarketStatus":{"tag":"盘前交易","tradingStatus":1,"beginTime":1745308800000},"marketStatusCode":0,"adr":0,"adjPreClose":0,"pbRate":9.286466,"peRate":32.45662,"turnoverRate":0.005474,"increases":3,"decrements":4,"flats":0,"marketCap":1310903118528,"floatMarketCap":1235170757472},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"BK4599\",,,,,undefined,":{"symbol":"BK4599","high":1257.6151,"amplitude":0.032776,"preClose":1251.235,"low":1216.6044,"pbRate":"9.286466","latestPrice":1229.1708,"volume":57826241,"delay":0,"open":1252.1276,"prevYearClose":1305.0607,"prevWeekClose":1251.235,"prevMonthClose":1314.3724,"prevQuarterClose":1314.3724,"fiveDayClose":1177.7317,"twentyDayClose":1358.6935,"sixtyDayClose":1290.7499,"secType":"PLATE","market":"US","turnoverRate":0.005474,"peRate":32.45662,"marketCap":1310903118528,"floatMarketCap":1235170757472,"timestamp":1745265599999,"nameCN":"减肥药"},"@#url:\"https://hq.skytigris.cn/api/global/plate/up_down\",method:\"POST\",data:#delay:false,bkCodes:@\"BK4599\",,,,undefined,":{"bkCode":"BK4599","up":3,"down":4,"flat":0},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"BK4599\",pageSize:20,pageCount:3,lang_content:\"cn\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2527123178","title":"辉瑞被减肥药“搞怕了”","url":"https://stock-news.laohu8.com/highlight/detail?id=2527123178","media":"Ofweek维科网","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2527123178?lang=zh_cn&edition=fundamental","pubTime":"2025-04-16 13:53","pubTimestamp":1744782824,"startTime":"0","endTime":"0","summary":"辉瑞决定取消Danuglipron的研发，核心原因在于，有1名患者可能受到药物诱导的肝损伤。2023年末，辉瑞公布Danuglipron治疗肥胖2b期临床的最新数据。市场认为，辉瑞遭遇打击之后，可能会继续收购减肥药资产，属于Viking们的机会来了。辉瑞并没有彻底放弃减肥药资产，目前其布局的管线中，一种口服小分子GIPR拮抗剂，处于2期开发阶段。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025041613534694d70573&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025041613534694d70573&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["LU0289739699.SGD","LU0122379950.USD","LU1066053197.SGD","IE00BBT3K403.USD","SG9999011175.SGD","LU0456855351.SGD","LU1023059063.AUD","LU0868494617.USD","BK4568","LU1057294990.SGD","SG9999013999.USD","BK4533","PFE","BK4581","IE00B19Z3B42.SGD","SG9999001176.SGD","LU0170899867.USD","BK4585","LU0234572021.USD","LU0321505868.SGD","LU1894683348.USD","IE0002270589.USD","BK4007","LU1066051498.USD","LU1894683264.USD","BK4599","SG9999003800.SGD","LU0225771236.USD","LU1883839398.USD","LU0321505439.SGD","IE000M9KFDE8.USD","BK4534","LU0225284248.USD","BK4588","IE00BLSP4452.SGD","SGXZ57979304.SGD","BK4592","LU0306806265.USD","IE00B19Z3581.USD","SG9999002232.USD","LU0306807586.USD","IE00BLSP4239.USD","BK4550","SG9999001176.USD","LU0058720904.USD","LU0985481810.HKD","SG9999002224.SGD"],"gpt_icon":1},{"id":"2527288993","title":"辉瑞4月15日成交额为11.68亿美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2527288993","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2527288993?lang=zh_cn&edition=fundamental","pubTime":"2025-04-16 10:13","pubTimestamp":1744769630,"startTime":"0","endTime":"0","summary":"美东时间2025年4月15日，辉瑞成交额为11.68亿美元，成交额较昨日减少14.48%，当日成交量为5181.47万股。辉瑞于2025年4月15日涨1.45%，报22.44美元，该股过去5个交易日涨2.75%，年初至今跌14.02%，过去60日跌13.26%。|近5个交易日成交情况||||#|日期|成交额（美元）|成交额较昨日变化|成交量（股）|#|2025-04-15|11.68亿|-14.48%|5181.47万|#|2025-04-14|13.66亿|14.34%|6190.09万|#|2025-04-11|11.95亿|-24.16%|5507.81万|#|2025-04-10|15.75亿|-24.50%|7296.07万|#|2025-04-09|20.87亿|30.20%|9595.44万|辉瑞是全球最大的制药公司之一，年销售额接近500亿美元。辉瑞在全球销售这些产品，国际销售额占其总销售额的近50%。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250416101358a45a7557&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250416101358a45a7557&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["LU0456855351.SGD","BK4599","LU0225771236.USD","LU0985481810.HKD","SG9999003800.SGD","SG9999013999.USD","LU0234572021.USD","IE0002270589.USD","SG9999011175.SGD","BK4581","IE000M9KFDE8.USD","LU0170899867.USD","SG9999001176.SGD","BK4568","LU0321505439.SGD","LU0058720904.USD","LU1894683264.USD","LU0225284248.USD","BK4592","LU1894683348.USD","BK4550","IE00BLSP4452.SGD","IE00BLSP4239.USD","LU0306806265.USD","LU0289739699.SGD","IE00BBT3K403.USD","LU1023059063.AUD","BK4585","PFE","LU1066053197.SGD","LU1057294990.SGD","LU0306807586.USD","SGXZ57979304.SGD","LU0122379950.USD","LU1883839398.USD","BK4007","IE00B19Z3581.USD","BK4588","BK4534","LU0321505868.SGD","SG9999002232.USD","SG9999001176.USD","LU0868494617.USD","BK4533","LU1066051498.USD","SG9999002224.SGD","IE00B19Z3B42.SGD"],"gpt_icon":1},{"id":"2527270288","title":"诺和诺德4月15日成交额为3.85亿美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2527270288","media":"市场透视","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2527270288?lang=zh_cn&edition=fundamental","pubTime":"2025-04-16 10:07","pubTimestamp":1744769277,"startTime":"0","endTime":"0","summary":"美东时间2025年4月15日，诺和诺德成交额为3.85亿美元，成交额较昨日减少27.86%，当日成交量为594.56万股。诺和诺德于2025年4月15日跌2.38%，报64.49美元，该股过去5个交易日涨4.69%，年初至今跌24.13%，过去60日跌17.07%。诺和诺德还有一个生物制药部门，专门从事血友病和其他疾病的蛋白质疗法。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250416100804a45a7382&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250416100804a45a7382&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["IE00BZ1G4Q59.USD","LU1093756325.SGD","BK4585","LU1093756168.USD","BK4007","BK4588","BK4599","NVO","BK4532","IE00BKVL7J92.USD","LU0154236417.USD"],"gpt_icon":1},{"id":"2527407051","title":"礼来4月15日成交额为18.62亿美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2527407051","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2527407051?lang=zh_cn&edition=fundamental","pubTime":"2025-04-16 09:48","pubTimestamp":1744768096,"startTime":"0","endTime":"0","summary":"美东时间2025年4月15日，礼来成交额为18.62亿美元，成交额较昨日减少28.31%，当日成交量为245.81万股。礼来于2025年4月15日涨0.38%，报757.18美元，该股过去5个交易日涨4.26%，年初至今跌1.75%，过去60日涨4.51%。|近5个交易日成交情况||||#|日期|成交额（美元）|成交额较昨日变化|成交量（股）|#|2025-04-15|18.62亿|-28.31%|245.81万|#|2025-04-14|25.98亿|-0.95%|346.12万|#|2025-04-11|26.23亿|-12.56%|360.34万|#|2025-04-10|29.99亿|-37.21%|418.27万|#|2025-04-09|47.77亿|57.32%|661.90万|礼来制药公司是一家专注于神经科学、心脏代谢、癌症和免疫学的制药公司。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250416094825a6bbeaf7&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250416094825a6bbeaf7&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["LU1127390331.HKD","SG9999014906.USD","LU2471134796.USD","LU1983299246.USD","LU1917777945.USD","LU1720051108.HKD","LU0943347566.SGD","LU2552382132.HKD","LU2237443465.HKD","LU1551013425.SGD","LU0198837287.USD","LU0203202063.USD","LU2471134523.USD","LU0122379950.USD","BK4599","LU0203201768.USD","LU0466842654.USD","LU2491049909.HKD","LU2237438978.USD","IE00B2B36J28.USD","LU0079474960.USD","LU2361044949.HKD","LU0471298694.HKD","LU0114720955.EUR","SG9999014898.SGD","LU2089984988.USD","BK4585","SG9999014914.USD","LLY","SG9999013999.USD","LU1267930730.SGD","BK4516","LU2461242641.AUD","LU2361045086.USD","LU0385154629.USD","LU0417517546.SGD","LU0456855351.SGD","LU2360106947.USD","LU2471134879.HKD","LU2468319806.SGD","SG9999001176.SGD","LU0096364046.USD","LU1868837300.USD","IE00BK4W5M84.HKD","LU2602419157.SGD","LU0061475181.USD","SG9999015978.USD","SG9999018857.SGD","LU0320765059.SGD","LU2237443895.HKD"],"gpt_icon":1},{"id":"2527409934","title":"安进4月15日成交额为7.64亿美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2527409934","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2527409934?lang=zh_cn&edition=fundamental","pubTime":"2025-04-16 09:15","pubTimestamp":1744766148,"startTime":"0","endTime":"0","summary":"美东时间2025年4月15日，安进成交额为7.64亿美元，成交额较昨日增加4.95%，当日成交量为259.36万股。安进于2025年4月15日涨0.47%，报295.3美元，该股过去5个交易日涨5.37%，年初至今涨14.21%，过去60日涨9.4%。安进于 2006 年推出了首款癌症治疗药物 Vectibix，并销售骨强化药物 Prolia/Xgeva和 Evenity。同时，安进还拥有不断增长的生物仿制药产品组合。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250416091610a45a622e&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250416091610a45a622e&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["LU1061106388.HKD","LU0868494617.USD","LU2089984988.USD","IE00BJJMRZ35.SGD","AMGN","LU2242652126.USD","SG9999001440.SGD","LU1057294990.SGD","BK4139","LU1571399168.USD","BK4534","LU2468319806.SGD","IE00BJT1NW94.SGD","LU2112291526.USD","LU0058720904.USD","IE0009355771.USD","LU2242646821.SGD","LU0109394709.USD","BK4599","LU0289739699.SGD","BK4566","LU0889565916.HKD","LU0122379950.USD","BK4588","BK4585","IE0002141913.USD","BK4581","BK4533","IE00BFTCPJ56.SGD","LU0320765992.SGD","LU1023059063.AUD","IE00B4R5TH58.HKD","IE00B2B36J28.USD","LU1983299246.USD"],"gpt_icon":0},{"id":"2527403040","title":"联邦制药(3933.HK)：UBT251授权给诺和诺德 创新转型初见成效","url":"https://stock-news.laohu8.com/highlight/detail?id=2527403040","media":"第一上海","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2527403040?lang=zh_cn&edition=fundamental","pubTime":"2025-04-16 08:01","pubTimestamp":1744761717,"startTime":"0","endTime":"0","summary":"生物药管线：利拉鲁肽25 年获批上市，德谷胰岛素26 年上市，司美格鲁肽糖尿病适应症报产，减重适应症进入临床三期；UBT251与诺和诺德达成授权合作，首付款2亿美元，潜在里程碑款18 亿美元。综上所述，25 年叠加UBT251首付款，公司整体收入及利润端有望稳中有升。24 年司美格鲁肽收入同比增长38%至293 亿美元。而礼来的替而泊肽SURMOUNT - 1 试验显示其15mg 剂量组72 周平均减重 20.9%。而UBT251 在1b 临床试验中显示其12 周即可以达到15.1%的降幅，具有潜在Best in Class 的可能。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250416080159a45a520c&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250416080159a45a520c&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["IE00BZ1G4Q59.USD","LU1093756168.USD","BK4532","BK4599","IE00BKVL7J92.USD","BK4585","BK4007","BK4588","LU1093756325.SGD","LU0154236417.USD","NVO"],"gpt_icon":1},{"id":"2527425919","title":"辉瑞因潜在肝脏损伤停止减肥药测试Pfizer Ends Testing of Obesity Pill After Possible Liver Injury","url":"https://stock-news.laohu8.com/highlight/detail?id=2527425919","media":"动脉网","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2527425919?lang=zh_cn&edition=fundamental","pubTime":"2025-04-16 01:35","pubTimestamp":1744738500,"startTime":"0","endTime":"0","summary":"Pfizer will now stop all testing of danuglipron, including its use with other drugs for obesity treatment. However, the company said it still plans to work on other obesity treatments that are in earlier stages of research.辉瑞将停止对丹纳格列波隆的所有测试，包括其与其他药物联合用于肥胖症治疗的测试。Even with recent price cuts, many of these medications still cost hundreds of dollars per month.即使近期价格有所下调，许多此类药物每月的费用仍高达数百美元。Pfizer had already stopped testing of a twice-daily version of danuglipron in late 2023 after more than half the people in a trial stopped taking it.辉瑞公司已于 2023 年底停止了每日两次服用的丹那列普隆的测试，当时试验中超过一半的人已停止服用该药。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202504160136159738d6c8&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202504160136159738d6c8&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["IE00BLSP4452.SGD","SG9999003800.SGD","IE000M9KFDE8.USD","BK4592","LU0225771236.USD","LU1023059063.AUD","LU1066051498.USD","LU0122379950.USD","BK4581","LU0456855351.SGD","BK4588","LU0058720904.USD","BK4599","IE0002270589.USD","LU0306806265.USD","PFE","LU0321505439.SGD","BK4568","LU1057294990.SGD","LU0868494617.USD","IE00B19Z3B42.SGD","SG9999011175.SGD","IE00B19Z3581.USD","BK4585","LU1894683348.USD","LU0170899867.USD","LU1883839398.USD","LU0985481810.HKD","SG9999001176.USD","SGXZ57979304.SGD","LU1894683264.USD","BK4550","SG9999002232.USD","LU0234572021.USD","LU0321505868.SGD","IE00BBT3K403.USD","SG9999002224.SGD","SG9999013999.USD","BK4533","LU0306807586.USD","LU0289739699.SGD","SG9999001176.SGD","BK4007","BK4534","LU0225284248.USD","IE00BLSP4239.USD","LU1066053197.SGD"],"gpt_icon":1},{"id":"2527230214","title":"诺和诺德盘中异动 大幅下挫3.01%","url":"https://stock-news.laohu8.com/highlight/detail?id=2527230214","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2527230214?lang=zh_cn&edition=fundamental","pubTime":"2025-04-16 01:17","pubTimestamp":1744737463,"startTime":"0","endTime":"0","summary":"北京时间2025年04月16日01时17分，诺和诺德股票出现波动，股价快速下跌3.01%。截至发稿，该股报64.07美元/股，成交量359.287万股，换手率0.08%，振幅2.82%。诺和诺德股票所在的制药行业中，整体跌幅为0.05%。诺和诺德公司简介：诺和诺德拥有全球约三分之一的品牌糖尿病治疗市场，是全球领先的糖尿病护理产品供应商。诺和诺德还有一个生物制药部门，专门从事血友病和其他疾病的蛋白质疗法。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250416011743aa2c7042&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250416011743aa2c7042&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["IE00BZ1G4Q59.USD","BK4532","LU1093756325.SGD","BK4588","LU0154236417.USD","LU1093756168.USD","BK4599","BK4007","BK4585","IE00BKVL7J92.USD","NVO"],"gpt_icon":1},{"id":"2527284114","title":"【LVMH集团跌超7%，在欧股“十一罗汉”中表现最差，并领跌一众奢侈品概念股】周二，阿斯麦控股荷兰阿姆斯特丹股价收涨2.61%，报605.40欧元。诺和诺德哥本哈根股价收跌2.34%，报425.70。LVMH集团收跌7.82%，欧莱雅跌2%，阿斯利康和赛诺菲至多跌0.39%，雀巢则收涨0.38%，罗氏、诺华、德国思爱普Sap、葛兰素史克至多涨1.78%。欧洲奢侈品概念股中，除了路易威登母公司LVMH集团之外，开云集团跌5.22%，博柏利跌4.55%，人头马君度、保乐力加、雨果博斯、斯沃琪集团、瑞士历峰集团跌3.69%-0.88%，爱马仕则收涨0.21%。","url":"https://stock-news.laohu8.com/highlight/detail?id=2527284114","media":"金融界","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2527284114?lang=zh_cn&edition=fundamental","pubTime":"2025-04-16 00:54","pubTimestamp":1744736061,"startTime":"0","endTime":"0","summary":"周二，阿斯麦控股荷兰阿姆斯特丹股价收涨2.61%，报605.40欧元。诺和诺德哥本哈根股价收跌2.34%，报425.70。LVMH集团收跌7.82%，欧莱雅跌2%，阿斯利康和赛诺菲至多跌0.39%，雀巢则收涨0.38%，罗氏、诺华、德国思爱普Sap、葛兰素史克至多涨1.78%。欧洲奢侈品概念股中，除了路易威登母公司LVMH集团之外，开云集团跌5.22%，博柏利跌4.55%，人头马君度、保乐力加、雨果博斯、斯沃琪集团、瑞士历峰集团跌3.69%-0.88%，爱马仕则收涨0.21%。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://24h.jrj.com.cn/2025/04/16005449565332.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"jinrongjie_stock","symbols":["IE00BFTCPJ56.SGD","LU0154236417.USD","IE0004445239.USD","LU2063271972.USD","IE00BJJMRZ35.SGD","LU0208291251.USD","BK4585","NVS","BK4007","BK4578","IE0002141913.USD","BK4543","LU2236285917.USD","LU2462157665.USD","IE00BZ1G4Q59.USD","LVMUY","GSK.UK","BK4568","03165","IE00BKVL7J92.USD","IE00BD6J9T35.USD","LU0823434740.USD","IE0009355771.USD","BK4599","LU0889565916.HKD","LU0345774631.USD","LU2417539215.USD","BK4202","BK4532","GSK","NSRGY","LRLCY","IE00B2B36J28.USD","IE00BJT1NW94.SGD","LU0097036916.USD","AZN","LU0345774391.USD","LU1093756325.SGD","LU0320765992.SGD","BK4147","IE00B4R5TH58.HKD","LU0211331839.USD","LU0070302665.USD","LU2456880835.USD","LU0823434583.USD","BK4212","LU0320765489.SGD","BK4588"],"gpt_icon":0},{"id":"2527435449","title":"Viking Therapeutics, Inc.盘中异动 股价大跌5.01%报23.34美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2527435449","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2527435449?lang=zh_cn&edition=fundamental","pubTime":"2025-04-15 23:03","pubTimestamp":1744729396,"startTime":"0","endTime":"0","summary":"北京时间2025年04月15日23时03分，Viking Therapeutics, Inc.股票出现异动，股价急速下跌5.01%。Viking Therapeutics, Inc.股票所在的生物技术行业中，整体跌幅为0.05%。其相关个股中，Mural Oncology Plc、Dogwood Therapeutics, Inc.、Skye Bioscience, Inc.涨幅较大，Mural Oncology Plc、Dogwood Therapeutics, Inc.、Metavia Inc.较为活跃，换手率分别为1006.37%、726.35%、235.68%，振幅较大的相关个股有Skye Bioscience, Inc.、Dogwood Therapeutics, Inc.、Mural Oncology Plc，振幅分别为171.53%、91.33%、86.41%。Viking Therapeutics, Inc.公司简介：Viking Therapeutics Inc 是一家医疗保健服务提供商。VK2809 和 VK0214 是甲状腺激素受体 β 的口服、组织和受体亚型选择性激动剂。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025041523031794d640c7&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025041523031794d640c7&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["LENZ","VKTX","BK4007","BK4139","BK4599","BK4585","BK4588"],"gpt_icon":0},{"id":"2527487864","title":"礼来：携手本土生态伙伴 加速赋能医药创新","url":"https://stock-news.laohu8.com/highlight/detail?id=2527487864","media":"证券日报","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2527487864?lang=zh_cn&edition=fundamental","pubTime":"2025-04-15 22:10","pubTimestamp":1744726243,"startTime":"0","endTime":"0","summary":"本报讯（记者金婉霞）4月15日，在第31届全国肿瘤防治宣传周上，礼来制药（下称“礼来”）中国总裁兼总经理德赫兰女士表示，礼来始终致力于为中国患者提供高质量的创新药物，将继续坚定地参与本土创新生态的建设，真正解决患者的未尽之需，为中国肿瘤防治事业及整个社会的发展创造价值。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202504153377662086.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["SG9999013999.USD","LU1057294990.SGD","LU1061106388.HKD","SG9999015986.USD","SGXZ99366536.SGD","LU2491050154.USD","BK4588","LU0061475181.USD","LU0943347566.SGD","LU0114720955.EUR","IE0009355771.USD","LU1548497426.USD","LU1127390331.HKD","LU0238689110.USD","SGXZ51526630.SGD","LU0820561909.HKD","SG9999014906.USD","LU2106854487.HKD","LU0354030511.USD","LU0256863811.USD","LU2237438978.USD","BK4599","LU1983299246.USD","LU0820561818.USD","BK4585","LU0354030438.USD","LU1023059063.AUD","LU0079474960.USD","LU0289739699.SGD","09939","LU2324357040.USD","LU1712237335.SGD","LLY","LU1035775433.USD","LU0689472784.USD","LU2089984988.USD","LU2237443465.HKD","LU2468319806.SGD","LU2361044949.HKD","SG9999014898.SGD","LU1232071149.USD","BK4533","LU2237443622.USD","LU2237443382.USD","IE00B1BXHZ80.USD","LU1551013425.SGD","SG9999015978.USD","LU0006306889.USD","IE00BFTCPJ56.SGD","BK4516"],"gpt_icon":1},{"id":"2527925413","title":"BUZZ-实验性减肥药物在小鼠体内显示出前景后，斯凯生物科学公司业绩上升","url":"https://stock-news.laohu8.com/highlight/detail?id=2527925413","media":"路透中文","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2527925413?lang=zh_cn&edition=fundamental","pubTime":"2025-04-15 20:20","pubTimestamp":1744719640,"startTime":"0","endTime":"0","summary":"4月15日 - ** 药物开发商Skye Bioscience SKYE.O的股价盘前上涨11.5%至1.46美元** 该公司称， ，其候选药物尼马单抗在小鼠体内显示出23.5%的体重减轻效果，与礼来LLY.N的流行药物tirzepatide和诺和诺德NOVOb.CO的实验药物monlunabant相当。由于自动化翻译可能有误，或未能包含所需语境，路透不保证自动化翻译文本的准确性，仅是为了便利读者而提供自动化翻译。对于因为使用自动化翻译功能而造成的任何损害或损失，路透不承担任何责任。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250415:nL4T3QT13L:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU1712237335.SGD","LU1983299246.USD","LU1917777945.USD","SKYE","LU1814569148.SGD","LU1127390331.HKD","BK4516","LU0417517546.SGD","SGXZ57979304.SGD","LU2265009873.SGD","LU0203202063.USD","LU1551013342.USD","LU0061475181.USD","LU1366192091.USD","BK4139","SG9999014914.USD","SG9999015978.USD","IE00BFTCPJ56.SGD","BK4581","LU2471134523.USD","IE0002141913.USD","IE00BK4W5L77.USD","LU1551013425.SGD","LU1061106388.HKD","LU1974910355.USD","LU2237443465.HKD","LU0456855351.SGD","BK4588","IE00BJT1NW94.SGD","SG9999018865.SGD","IE00BJJMRZ35.SGD","SG9999015952.SGD","LU2471134952.CNY","SG9999017495.SGD","IE00BK4W5M84.HKD","LU1069344957.HKD","LU1623119135.USD","LU0943347566.SGD","LU0079474960.USD","LU2063271972.USD","LU2237443382.USD","LU0820561818.USD","LU2237443978.SGD","SGXZ51526630.SGD","BK4533","LU1280957306.USD","LU1868836914.USD","BK4599","LU0471298777.SGD"],"gpt_icon":1},{"id":"2527499611","title":"1名受试者出现肝损伤，辉瑞终止一款口服减肥药临床开发，死磕小分子GLP-1","url":"https://stock-news.laohu8.com/highlight/detail?id=2527499611","media":"时代财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2527499611?lang=zh_cn&edition=fundamental","pubTime":"2025-04-15 18:55","pubTimestamp":1744714542,"startTime":"0","endTime":"0","summary":"一款口服减重药折戟。图片来源：图虫创意跨国药企辉瑞又终止一款口服GLP-1R激动剂的临床开发。时代财经从辉瑞获悉，美国时间4月14日，辉瑞宣布决定终止开发每日一次的口服GLP-1R激动剂Danuglipron，该药物用于减重管理。由于安全性问题待解，辉瑞经多方考虑后选择终止开发这一小分子药物。而在Danuglipron之前，早在2023年6月，辉瑞就终止了其旗下另一款GLP-1R小分子激动剂项目Lotiglipron的后续研发。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250415185615973879d2&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250415185615973879d2&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["LU0456855351.SGD","LU0306807586.USD","LU1066051498.USD","LU0985481810.HKD","SG9999011175.SGD","BK4144","IE00BLSP4452.SGD","BK4585","BK4599","LU1894683264.USD","LU1057294990.SGD","SG9999001176.USD","BK4590","SGXZ57979304.SGD","GLP","IE00BBT3K403.USD","LU1894683348.USD","BK4581","BK4533","BK4534","BK4588","LU0306806265.USD","IE00B19Z3B42.SGD","LU1883839398.USD","SG9999001176.SGD","BK4007","LU0225284248.USD","LU0868494617.USD","IE00B19Z3581.USD","SG9999013999.USD","IE000M9KFDE8.USD","BK4550","IE00BLSP4239.USD","IE0002270589.USD","LU0225771236.USD","LU1066053197.SGD","LU0321505439.SGD","LU0234572021.USD","SG9999002224.SGD","LU0170899867.USD","LU0289739699.SGD","BK4568","SG9999003800.SGD","LU1023059063.AUD","LU0122379950.USD","PFE","BK4592","SG9999002232.USD","LU0321505868.SGD","LU0058720904.USD"],"gpt_icon":1},{"id":"2527745364","title":"辉瑞(PFE.US)研发受挫引发收购猜测 减肥药新贵股价大涨","url":"https://stock-news.laohu8.com/highlight/detail?id=2527745364","media":"智通财经","labels":["merge"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2527745364?lang=zh_cn&edition=fundamental","pubTime":"2025-04-15 15:04","pubTimestamp":1744700695,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，辉瑞停止开发备受关注的口服减肥药Danuglipron，投资者押注这一挫折可能会刺激辉瑞寻求并购交易，几家开发减肥药的生物技术公司股价周一上涨。辉瑞此前表示，将停止开发备受关注的口服减肥药Danuglipron，因为一名参加临床试验的患者出现了潜在的药物性肝损伤。辉瑞一直试图与诺和诺德和礼来在减肥治疗市场竞争，但该公司在研发减肥药物方面已经落后于竞争对手。Danuglipron研发终止可能会使辉瑞的产品组合出现缺口。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1278756.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"merge","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["LU0306806265.USD","LU1023059063.AUD","LU0985481810.HKD","LU0289739699.SGD","LU1883839398.USD","SG9999003800.SGD","LU1057294990.SGD","BK4533","PFE","IE00BBT3K403.USD","IE00B19Z3581.USD","SG9999002232.USD","LU0122379950.USD","BK4581","BK4599","BK4568","SG9999002224.SGD","LU0456855351.SGD","LU0225771236.USD","LU0058720904.USD","LU0170899867.USD","IE00BLSP4452.SGD","SG9999001176.SGD","BK4550","BK4534","LU0321505439.SGD","LU0234572021.USD","LU0306807586.USD","SG9999013999.USD","LU1066053197.SGD","LU0868494617.USD","BK4007","LU1066051498.USD","IE00BLSP4239.USD","IE00B19Z3B42.SGD","LU1894683264.USD","BK4588","LU0321505868.SGD","IE0002270589.USD","LU1894683348.USD","SG9999011175.SGD","BK4592","IE000M9KFDE8.USD","SGXZ57979304.SGD","SG9999001176.USD","BK4585","LU0225284248.USD"],"gpt_icon":1},{"id":"2527341315","title":"辉瑞又双叒叕放弃一款口服 GLP-1，肥胖管线仅剩 1 款药物","url":"https://stock-news.laohu8.com/highlight/detail?id=2527341315","media":"Insight数据库","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2527341315?lang=zh_cn&edition=fundamental","pubTime":"2025-04-15 11:45","pubTimestamp":1744688751,"startTime":"0","endTime":"0","summary":"当地时间 4 月 14 日，辉瑞宣布终止开发口服胰高血糖素样肽-1受体激动剂 Danuglipron。安慰剂校正后，32 周时平均体重下降 8% 至 13%，26 周时平均体重下降 5% 至 9.5%。然而此次出现的潜在肝损伤病例，每日一次的Danuglipron 也终被辉瑞放弃。Danuglipron 并不是辉瑞在肥胖领域首次折戟的药物。在先后终止 Lotiglipron 和Danuglipron 开发后，目前辉瑞的肥胖药物管线仅剩一款口服 GIPR 拮抗剂PF-07976016，全球最高状态处于临床 II 期。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250415200413a459a994&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250415200413a459a994&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["LU0122379950.USD","BK4592","BK4144","LU0306806265.USD","LU1066051498.USD","LU0289739699.SGD","SG9999002224.SGD","LU0456855351.SGD","IE00BLSP4452.SGD","SG9999011175.SGD","LU0321505868.SGD","SG9999002232.USD","SG9999013999.USD","LU1894683264.USD","BK4534","IE00BBT3K403.USD","LU0321505439.SGD","LU0225284248.USD","LU1023059063.AUD","BK4568","BK4581","SGXZ57979304.SGD","LU0225771236.USD","LU0306807586.USD","IE0002270589.USD","BK4533","BK4590","PFE","LU1883839398.USD","SG9999001176.SGD","IE00B19Z3B42.SGD","LU0868494617.USD","BK4007","IE000M9KFDE8.USD","BK4588","IE00B19Z3581.USD","GLP","LU0058720904.USD","LU1066053197.SGD","LU1057294990.SGD","LU1894683348.USD","SG9999003800.SGD","LU0985481810.HKD","BK4585","BK4599","LU0234572021.USD","SG9999001176.USD","LU0170899867.USD","IE00BLSP4239.USD","BK4550"],"gpt_icon":1},{"id":"2527010965","title":"辉瑞4月14日成交额为13.66亿美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2527010965","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2527010965?lang=zh_cn&edition=fundamental","pubTime":"2025-04-15 10:09","pubTimestamp":1744682987,"startTime":"0","endTime":"0","summary":"美东时间2025年4月14日，辉瑞成交额为13.66亿美元，成交额较昨日增加14.34%，当日成交量为6190.09万股。辉瑞于2025年4月14日涨0.96%，报22.12美元，该股过去5个交易日跌2.25%，年初至今跌15.24%，过去60日跌15.11%。|近5个交易日成交情况||||#|日期|成交额（美元）|成交额较昨日变化|成交量（股）|#|2025-04-14|13.66亿|14.34%|6190.09万|#|2025-04-11|11.95亿|-24.16%|5507.81万|#|2025-04-10|15.75亿|-24.50%|7296.07万|#|2025-04-09|20.87亿|30.20%|9595.44万|#|2025-04-08|16.03亿|-17.07%|7240.60万|辉瑞是全球最大的制药公司之一，年销售额接近500亿美元。辉瑞在全球销售这些产品，国际销售额占其总销售额的近50%。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250415100950a6bab065&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250415100950a6bab065&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["LU0456855351.SGD","BK4599","LU0225771236.USD","LU0985481810.HKD","SG9999003800.SGD","SG9999013999.USD","LU0234572021.USD","IE0002270589.USD","SG9999011175.SGD","BK4581","IE000M9KFDE8.USD","LU0170899867.USD","SG9999001176.SGD","BK4568","LU0321505439.SGD","LU0058720904.USD","LU1894683264.USD","LU0225284248.USD","BK4592","LU1894683348.USD","BK4550","IE00BLSP4452.SGD","IE00BLSP4239.USD","LU0306806265.USD","LU0289739699.SGD","IE00BBT3K403.USD","LU1023059063.AUD","BK4585","PFE","LU1066053197.SGD","LU1057294990.SGD","LU0306807586.USD","SGXZ57979304.SGD","LU0122379950.USD","LU1883839398.USD","BK4007","IE00B19Z3581.USD","BK4588","BK4534","LU0321505868.SGD","SG9999002232.USD","SG9999001176.USD","LU0868494617.USD","BK4533","LU1066051498.USD","SG9999002224.SGD","IE00B19Z3B42.SGD"],"gpt_icon":1},{"id":"2527109468","title":"诺和诺德4月14日成交额为5.33亿美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2527109468","media":"市场透视","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2527109468?lang=zh_cn&edition=fundamental","pubTime":"2025-04-15 10:04","pubTimestamp":1744682657,"startTime":"0","endTime":"0","summary":"美东时间2025年4月14日，诺和诺德成交额为5.33亿美元，成交额较昨日减少27.17%，当日成交量为806.73万股。诺和诺德于2025年4月14日涨2.05%，报66.06美元，该股过去5个交易日涨3.8%，年初至今跌22.29%，过去60日跌19.53%。诺和诺德还有一个生物制药部门，专门从事血友病和其他疾病的蛋白质疗法。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250415100423a6baaf7c&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250415100423a6baaf7c&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4007","IE00BZ1G4Q59.USD","BK4599","IE00BKVL7J92.USD","LU1093756168.USD","BK4585","BK4588","BK4532","LU1093756325.SGD","NVO","LU0154236417.USD"],"gpt_icon":1},{"id":"2527436727","title":"辉瑞的GLP失败了","url":"https://stock-news.laohu8.com/highlight/detail?id=2527436727","media":"生物药大时代","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2527436727?lang=zh_cn&edition=fundamental","pubTime":"2025-04-15 09:44","pubTimestamp":1744681496,"startTime":"0","endTime":"0","summary":"4月14日，辉瑞宣布终止开发口服胰高血糖素样肽-1受体激动剂danuglipron，该药物此前正在研究用于慢性体重管理。在审查了所有信息，包括迄今为止为danuglipron生成的所有临床数据和监管机构的最新沟通后，辉瑞决定停止该分子的开发。市场对辉瑞制药撤回danuglipron的反应似乎有利于维京医疗、礼来和诺和诺德公司，因为慢性体重管理GLP-1受体激动剂领域的竞争可能会减少。因此，投资者对这些可能填补辉瑞制药退出这一药物类别留下空白的公司表现出更大兴趣。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250415131247a4594490&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250415131247a4594490&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4568","BK4588","SG9999013999.USD","SG9999002224.SGD","LU0321505439.SGD","SG9999001176.USD","LU0306806265.USD","IE00BBT3K403.USD","BK4599","LU1066051498.USD","LU1066053197.SGD","PFE","SG9999001176.SGD","IE00BLSP4452.SGD","BK4534","IE00B19Z3581.USD","SG9999002232.USD","BK4007","LU0868494617.USD","LU0170899867.USD","LU0225284248.USD","GLP","IE0002270589.USD","LU0234572021.USD","LU0456855351.SGD","LU1883839398.USD","BK4590","IE00B19Z3B42.SGD","BK4533","SG9999003800.SGD","LU1894683348.USD","LU0122379950.USD","LU0058720904.USD","LU1894683264.USD","SG9999011175.SGD","LU1057294990.SGD","IE000M9KFDE8.USD","BK4144","BK4550","IE00BLSP4239.USD","LU0306807586.USD","LU0289739699.SGD","LU0985481810.HKD","BK4581","LU0321505868.SGD","BK4592","BK4585","LU1023059063.AUD","SGXZ57979304.SGD","LU0225771236.USD"],"gpt_icon":1},{"id":"2527172422","title":"安进4月14日成交额为7.28亿美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2527172422","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2527172422?lang=zh_cn&edition=fundamental","pubTime":"2025-04-15 09:15","pubTimestamp":1744679747,"startTime":"0","endTime":"0","summary":"美东时间2025年4月14日，安进成交额为7.28亿美元，成交额较昨日减少26.10%，当日成交量为249.30万股。安进于2025年4月14日涨2.78%，报293.92美元，该股过去5个交易日涨1.46%，年初至今涨13.68%，过去60日涨9.97%。安进于 2006 年推出了首款癌症治疗药物 Vectibix，并销售骨强化药物 Prolia/Xgeva和 Evenity。同时，安进还拥有不断增长的生物仿制药产品组合。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250415091604a4591a97&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250415091604a4591a97&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4534","IE00BFTCPJ56.SGD","BK4588","LU0122379950.USD","IE0002141913.USD","BK4581","BK4566","LU1057294990.SGD","IE0009355771.USD","LU2468319806.SGD","LU1061106388.HKD","LU2242652126.USD","LU0868494617.USD","IE00B2B36J28.USD","LU0320765992.SGD","BK4139","BK4585","BK4533","AMGN","IE00BJJMRZ35.SGD","SG9999001440.SGD","LU1023059063.AUD","IE00B4R5TH58.HKD","LU0058720904.USD","LU2089984988.USD","LU0889565916.HKD","LU2242646821.SGD","LU0289739699.SGD","LU1983299246.USD","LU2112291526.USD","BK4599","LU0109394709.USD","IE00BJT1NW94.SGD","LU1571399168.USD"],"gpt_icon":0},{"id":"2527652791","title":"金十数据整理：每日美股市场要闻速递（4月14日，周一）","url":"https://stock-news.laohu8.com/highlight/detail?id=2527652791","media":"美港电讯","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2527652791?lang=zh_cn&edition=fundamental","pubTime":"2025-04-14 21:00","pubTimestamp":1744635658,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.ushknews.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_meigang","symbols":["03347","LU1917777945.USD","LU0528227936.USD","X","LU0323591593.USD","LU2247934214.USD","LU1064131342.USD","PFE","BK4077","IE00B7KXQ091.USD","LU1206712785.SGD","LU2077746001.SGD","BK4599","LLY","LU0795875169.SGD","LU0784385840.USD","LU0354030511.USD","IE00B19Z8W00.USD","CHA","IE00BJJMRX11.SGD","LU1496350502.SGD","AAPL","LU0314106906.USD","LU2237443549.SGD","LU1582987597.SGD","LU0314104364.USD","LU1861559042.SGD","LU1670710588.SGD","LU1668664300.SGD","LU2602419157.SGD","LU1564329115.USD","LU0109391861.USD","LU1989764664.SGD","LU0823421333.USD","BK4504","SONY","LU2065171402.SGD","LU1989772923.USD","INTC","LU2237438978.USD","MACW.SI","LU0820562030.AUD","LU1267930490.SGD","LU0079474960.USD","LU1316542783.SGD","FTC","IE00BKDWB100.SGD","BK4592","LU1935042215.USD","META"],"gpt_icon":1}],"pageSize":20,"totalPage":6,"pageCount":3,"totalSize":118,"code":"91000000","status":"200"}]}}